UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY

Registered charity 1148145 · accounts filings on the Charity Commission register · also known as UKI NETS

To promote professional and public awareness of NET throughout the UK and Ireland with the aim of optimising patient care and outcomes. This will be achieved through research, education, communications and patient and professional advocacy, working with other professional bodies, charities, patient groups and governments.

Objects

THE SOCIETY'S OBJECTS ARE TO PROMOTE FOR THE PUBLIC BENEFIT RESEARCH, EDUCATION AND IMPROVED QUALITY OF CLINICAL PRACTICE IN NEUROENDOCRINE TUMOURS BY THE ORGANISATION OF CONFERENCES, TRAINING COURSES AND PUBLICATIONS, BY RAISING PUBLIC AWARENESS, LIAISON WITH NATIONAL AND INTERNATIONAL LEGISLATORS, AND BY ANY OTHER APPROPRIATE MEANS. THE SOCIETY AIMS TO IMPROVE THE DIAGNOSIS, THERAPY AND SURVIVORSHIP OF PATIENTS WITH NEUROENDOCRINE TUMOURS WITHIN A NATIONAL MULTIDISCIPLINARY AND SCIENTIFIC CONTEXT.

The charity’s charitable objects and area of benefit, quoted from its governing document as held on the Charity Commission register.

Causes: Education/training · The Advancement Of Health Or Saving Of Lives · website · Get email alerts

Latest income
£128k
Latest spending
£122k
Registered
2012
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that the charity ended the year with £168,917 in unrestricted funds, which the trustees deem sufficient to cover management, administration, and support costs. The charity reported a net income of £6,458 for the year, having spent £121,502 against income of £127,960. The reserves policy targets a minimum of two years' expenditure to ensure financial viability.

Automated summary of the FY2025 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Largest income source: Charitable activities (81% of income)
“Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions.” — page 6
Per its FY2025 accounts as filed with the Charity Commission.
Reserves policy: two years' expenditure (held: £169k)
“That level is currently deemed to be one that equates to a minimum of two years’ expenditure.”
Per its FY2025 accounts as filed with the Charity Commission.

Accounts independently examined (not a full audit). Discloses 5 of 6 completeness components.

Policies the charity declares

In its annual return the charity told the Commission that it has the policies listed below. This is self-declared: it is not verified by the Commission or by this site, and it is not evidence of how a policy works in practice.

Trustees · trustee networks

Trustee list from the Charity Commission register (current, not historical).

Operates in: Ireland · Northern Ireland · Scotland · Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/08/2025£128k£122k
31/08/2024£137k£122k
31/08/2023£58k£70k
31/08/2022£98k£86k
31/08/2021£95k£86k

Common questions

Is UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY financially healthy?

Per its FY2025 accounts: The accounts state that the charity ended the year with £168,917 in unrestricted funds, which the trustees deem sufficient to cover management, administration, and support costs. The charity reported a net income of £6,458 for the year, having spent £121,502 against income of £127,960. The reserves policy targets a minimum of two years' expenditure to ensure financial viability. Its FY2025 accounts were independently examined.